ATE388700T1 - Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren - Google Patents

Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren

Info

Publication number
ATE388700T1
ATE388700T1 AT04014650T AT04014650T ATE388700T1 AT E388700 T1 ATE388700 T1 AT E388700T1 AT 04014650 T AT04014650 T AT 04014650T AT 04014650 T AT04014650 T AT 04014650T AT E388700 T1 ATE388700 T1 AT E388700T1
Authority
AT
Austria
Prior art keywords
dilators
venous
arterial
therapeutic compositions
vasoconstriction
Prior art date
Application number
AT04014650T
Other languages
English (en)
Inventor
Wayne H Kaesemeyer
Original Assignee
Angiogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenix Inc filed Critical Angiogenix Inc
Application granted granted Critical
Publication of ATE388700T1 publication Critical patent/ATE388700T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04014650T 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren ATE388700T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/321,051 US5543430A (en) 1994-10-05 1994-10-05 Method and formulation of stimulating nitric oxide synthesis

Publications (1)

Publication Number Publication Date
ATE388700T1 true ATE388700T1 (de) 2008-03-15

Family

ID=23248976

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95938157T ATE287212T1 (de) 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
AT04014650T ATE388700T1 (de) 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95938157T ATE287212T1 (de) 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren

Country Status (12)

Country Link
US (2) US5543430A (de)
EP (2) EP1552745B1 (de)
JP (1) JPH10507443A (de)
AT (2) ATE287212T1 (de)
AU (1) AU705002B2 (de)
CA (1) CA2201784C (de)
DE (2) DE69533940T2 (de)
DK (1) DK0784429T3 (de)
ES (1) ES2236716T3 (de)
MX (1) MX9702527A (de)
PT (1) PT784429E (de)
WO (1) WO1996010910A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945452A (en) * 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US6911427B1 (en) * 1995-09-15 2005-06-28 Duke University No-modified hemoglobins and uses therefore
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6297273B1 (en) 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US7968140B2 (en) * 1997-09-08 2011-06-28 Mars, Incorporated Chocolates and chocolate liquor having an enhanced polyphenol content
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6436996B1 (en) 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
AU9596698A (en) 1997-10-15 1999-05-03 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US6805883B2 (en) 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
US8507018B2 (en) * 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
EP1150669A4 (de) * 1999-02-05 2005-06-22 Angiogenix Inc Formulierungen auf l-argininbasis zur krankheitsbehandlung und deren verwendungsmethoden
JP2002539257A (ja) * 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド 薬剤の脳内生物学的利用率の増加
US6162237A (en) * 1999-04-19 2000-12-19 Chan; Winston Kam Yew Temporary intravascular stent for use in retrohepatic IVC or hepatic vein injury
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US6605115B1 (en) * 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
CA2404909A1 (en) 2000-04-12 2001-10-25 Caroline L. Jones Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6284790B1 (en) 2000-06-15 2001-09-04 Sachin Gupte Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
AP1682A (en) 2000-08-11 2006-11-27 David R Whitlock Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same.
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US20030228564A1 (en) * 2001-05-30 2003-12-11 Edrich Richard Alan Nitric oxide in a pathogen inactivation process
US20050244382A9 (en) * 2002-01-11 2005-11-03 Whitlock David R Compositions including ammonia oxidizing bacteria and methods of using same
US7079888B2 (en) * 2002-04-11 2006-07-18 Ansar, Inc. Method and apparatus for monitoring the autonomic nervous system using non-stationary spectral analysis of heart rate and respiratory activity
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
EP1562555A2 (de) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. L-arginin-formulierungen mit verzögerterfreisetzung und herstellungs- und verwendungsverfahren dafür
WO2005035001A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US7214390B2 (en) * 2003-02-07 2007-05-08 Barmensen Labs, Llc Topical compositions for enhancing sexual responsiveness
US20040254238A1 (en) * 2003-04-07 2004-12-16 Osteoscreen Bone growth stimulation with NO/statin and other NO modulating combinations
WO2005030147A2 (en) * 2003-09-26 2005-04-07 Whitlock David R Methods of using ammonia oxidizing bacteria
US20050095196A1 (en) * 2003-10-29 2005-05-05 Black Keith L. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
EP1732577B1 (de) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topische verabreichung von l-arginin zur verbesserung des aussehens von körper und haut
JP2007526316A (ja) * 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
WO2006055726A2 (en) * 2004-11-17 2006-05-26 Lindsey Berkson Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations
US7731993B2 (en) * 2004-11-17 2010-06-08 Lindsey Berkson Composition for treating a dermal anomaly
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
US10646508B1 (en) 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
US8569369B2 (en) 2007-09-18 2013-10-29 Thermolife International, Llc Amino acid compounds
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
KR20170005155A (ko) * 2008-01-31 2017-01-11 반더빌트유니버시티 폐의 용태에 따른 치료 방법
PL2240170T3 (pl) * 2008-01-31 2019-11-29 Univ Vanderbilt Sposoby i kompozycje do leczenia wieńcowego i tętniczego tętniakowego krwotoku podpajęczynówkowego
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2658551B1 (de) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Behandlung von erektionsstörungen und anderen indikationen
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
US12612370B2 (en) 2011-03-02 2026-04-28 Thermolife International, Llc Amino acid compositions
US8936635B2 (en) 2011-03-23 2015-01-20 Palmetto Pharmaceuticals Llc Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents
PL2696865T3 (pl) 2011-04-13 2017-07-31 Thermolife International, Llc Sposoby zastosowania N-acetylo beta-alaniny
CN106456678A (zh) 2014-04-15 2017-02-22 Ao生物医学有限责任公司 氨氧化型亚硝化单胞菌菌株d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
JP2024541338A (ja) 2020-11-12 2024-11-08 サーモライフ インターナショナル， エルエルシー 血中酸素飽和度を増大させる方法
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
EP4291206A4 (de) 2021-02-11 2025-01-08 Thermolife International, LLC Verfahren zur verabreichung von stickoxidgas
CN117731607A (zh) * 2023-12-20 2024-03-22 南京海纳医药科技股份有限公司 一种硝普钠注射液及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
US5059712A (en) * 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
US5132453A (en) * 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5273875A (en) * 1991-03-22 1993-12-28 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5132407A (en) * 1991-09-26 1992-07-21 Cornell Research Foundation, Inc. Purified inducible nitric oxide synthase flavoprotein
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
US5281627A (en) * 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof

Also Published As

Publication number Publication date
EP0784429A1 (de) 1997-07-23
MX9702527A (es) 1998-02-28
DK0784429T3 (da) 2005-05-23
ES2236716T3 (es) 2005-07-16
DE69533940T2 (de) 2005-12-22
PT784429E (pt) 2005-05-31
JPH10507443A (ja) 1998-07-21
EP1552745B1 (de) 2008-03-12
EP0784429A4 (de) 2001-02-07
AU3889695A (en) 1996-05-02
DE69535734D1 (de) 2008-04-24
WO1996010910A1 (en) 1996-04-18
US5543430A (en) 1996-08-06
EP0784429B1 (de) 2005-01-19
CA2201784A1 (en) 1996-04-18
ATE287212T1 (de) 2005-02-15
US5767160A (en) 1998-06-16
EP1552745A1 (de) 2005-07-13
AU705002B2 (en) 1999-05-13
CA2201784C (en) 2004-08-24
DE69533940D1 (de) 2005-02-24

Similar Documents

Publication Publication Date Title
ATE287212T1 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
ATE80043T1 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE3485581D1 (de) Antioestrogenes arzneimittel zur perkutanen verabreichung.
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
NO920395D0 (no) Terapeutisk aktive benzyloksyfenyl-derivater og fremgangsmaate for deres fremstilling
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
GEP20043374B (en) Medicinal Means on the Base of Honey, Their Use and Method for Production Thereof
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
RU93053982A (ru) Мазь для лечения открытых ран
RU94042230A (ru) Производные 1,3,4-оксадиазол-2-(3н)-она, их приготовление и применение в терапии
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
RU2177307C1 (ru) Лечебно-косметическое средство
NL7513892A (en) Ascorbic acid medicaments for external use - as nasal decongestants and to promote resistance to infection
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии
KR880000094A (ko) 위염치료제

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties